Deciphera Pharma advancing cancer candidate DCC-3014 [Seeking Alpha]
Deciphera Pharmaceuticals, Inc. (DCPH)
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
deciphera.com/investor-relations
Company Research
Source: Seeking Alpha
Results from a Phase 1 clinical trial evaluating Deciphera Pharmaceuticals' (NASDAQ: DCPH ) DCC-3014, a small molecule switch control inhibitor that selectively binds to the CSF1R switch pocket, in patients with advanced cancers showed encouraging action. Pharmacokinetic data demonstrated dose-proportional exposure that supports twice-weeking maintenance dosing (after a five-day lead-in). Biomarker data showed strong engagement of CSF1R. DCC-3014 was generally well-tolerated with no dose-limiting toxicities observed. A maximum tolerated dose has not been reached. The company plans to expand enrollment to include patients with tenosynovial giant cell tumors and explore combinations with other therapies. Additional data will be submitted for presentation at a future medical conference. Click to subscribe to real-time analytics on DCPH Now read: Is Arrowhead The Biotech Play You've Been Waiting For? » Subscribe for full text news in your inbox
Show less
Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCPH alerts
High impacting Deciphera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
DCPH
News
- Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Appoints Patricia Allen to its Board of Directors [Financial Post (Toronto, Ontario, Canada)]Financial Post
DCPH
Earnings
- 2/6/24 - Beat
DCPH
Sec Filings
- 2/20/24 - Form 4
- 2/20/24 - Form 4
- 2/20/24 - Form 4
- DCPH's page on the SEC website